Tvardi Therapeutics (TVRD) EBT: 2013-2017
Historic EBT for Tvardi Therapeutics (TVRD) over the last 5 years, with Sep 2017 value amounting to -$12.6 million.
- Tvardi Therapeutics' EBT fell 8.55% to -$12.6 million in Q3 2017 from the same period last year, while for Sep 2017 it was -$66.3 million, marking a year-over-year decrease of 46.44%. This contributed to the annual value of -$57.7 million for FY2016, which is 130.19% down from last year.
- Per Tvardi Therapeutics' latest filing, its EBT stood at -$12.6 million for Q3 2017, which was down 35.34% from -$9.3 million recorded in Q2 2017.
- In the past 5 years, Tvardi Therapeutics' EBT registered a high of $5.3 million during Q2 2013, and its lowest value of -$22.2 million during Q1 2017.
- In the last 3 years, Tvardi Therapeutics' EBT had a median value of -$10.8 million in 2016 and averaged -$11.5 million.
- In the last 5 years, Tvardi Therapeutics' EBT plummeted by 168.76% in 2014 and then rose by 29.28% in 2017.
- Tvardi Therapeutics' EBT (Quarterly) stood at -$2.1 million in 2013, then plummeted by 105.82% to -$4.3 million in 2014, then crashed by 124.32% to -$9.7 million in 2015, then crashed by 129.01% to -$22.2 million in 2016, then dropped by 8.55% to -$12.6 million in 2017.
- Its EBT was -$12.6 million in Q3 2017, compared to -$9.3 million in Q2 2017 and -$22.2 million in Q1 2017.